Benzinga | Oct 7, 2021 07:51AM EDT

Eledon Pharmaceuticals Announces Presentation On AT-1501 At The Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held virtually on October 7, 2021. Dr. Steve Perrin, Eledon's President and Chief Scientific Officer, will participate in an industry panel roundtable discussing ALS clinical trial design, biomarkers and endpoints. In addition, a poster will be presented on the AT-1501 Phase 2 study in adults with ALS.

Registration for the roundtable and additional information can be found on the NEALS website at https://www.neals.org/for-als-researchers/annual-neals-meeting/.

A copy of the poster can be found on the Investor section of the Company's website at https://ir.eledon.com/events-and-presentations/presentations.